ReportEndorphins in male impotence: Evidence for naltrexone stimulation of erectile activity in patient therapy
References (44)
A clinical study of “coital anxiety” in male potency disorders
Psychosom Res
(1969)- et al.
Opiate receptor binding sites in human spinal cord
Brain Res
(1983) - et al.
Penile blood pressure in the evaluation of erectile impotence
Fertil Steril
(1978) - et al.
Vasculogenic impotence: role of the pelvic steal test
J Urol
(1982) - et al.
Effects of morphine, beta-endorphin and naloxone on catecholamine levels and sexual behavior in the male rat
Pharm Biochem Behav
(1980) - et al.
Beta-endorphin and male sexual behavior
Eur J Pharmacol
(1977) - et al.
Facilitation by opiate antagonists of sexual performance in the male rat
Pharm Biochem Behav
(1979) - et al.
Facilitation of copulatory performance in male rats by naloxone: effects of hypophysectomy, 17-alpha-estradiol, and luteinizing hormone releasing hormone
Pharm Biochem Behav
(1980) Methadone reduces sexual performance and sexual motivation in the male syrian golden hamster
Pharm Biochem Behav
(1981)- et al.
ACTH, beta-endorphin and met-enkephalin: peripheral modification during the stress of human labor
Psychoneuroendocrinology
(1985)
Inhibition of copulatory behavior in male rat by D-Ala-Met-enkephalinamide
Life Sci
Localization of CRF-ir perikaraya and ACTH-ir fibers in rat brain
Brain Res
The role of Minnesota Multiphasic Personality Inventory in evaluation of erectile dysfunction
J Urol
Effect of testosterone undecanoate on sexual potency and the hypothalamic pituitary gonadal axis of impotent males
Arch Sex Behav
Inhibition of luteinizing hormone release by morphine and endogenous opiates in cultured pituitary cells
Endocrinology
Beta-endorphin: cellular localisation, electrophysiological and behavioral effects
Alpha-2-adrenergic and opiate receptor blockade
Arch Gen Psychiatry
Methadone dose and human sexual behavior
Int J Addict
Sexual behavior in heroin addiction and methadone maintenance
NY State J Med
A double blind cross over trial of gonadotropin releasing hormone (LHRH) in sexually impotent men
Clin Endocrinol
Psychopathology and endorphins
Adv Biochem Psychopharm
Sistemi a radioligandi in endocrinologia
Cited by (61)
The association of medications and supplements with human male reproductive health: a systematic review
2023, Fertility and SterilityHarm Reduction in Sexual Medicine
2022, Sexual Medicine ReviewsCitation Excerpt :In methadone treatment, methadone itself can induce disruption of the hypothalamic-pituitary-gonadal axis.128–130 ED is highly prevalent among subjects undergoing opioid maintenance therapy, with some studies reporting between half and two thirds of treated patients reporting some degree of erection impairment.131–133 Studies in women undergoing the same treatment have shown similar results, with 56.6% prevalence of female sexual dysfunction.134
Opioids and reproduction
2019, Vitamins and HormonesCitation Excerpt :As such, the opiate-mediated effect on sex steroid levels and consequently on sexual function, desire and behavior is seen in both chronic opiate users requiring pain therapy as well as in opioid addicts (Daniell, 2002; Paice, Penn, & Ryan, 1994). There is some evidence suggesting that the opioid antagonist naltrexone can improve symptoms of sexual dysfunction in otherwise healthy men although the effect ceases when patients go off treatment (Fabbri et al., 1989). It is recommended to carefully monitor men as well as women with opioid-induced hypogonadism and—after thorough risk-benefit-evaluation—initiate hormone replacement therapy to prevent long-term detrimental effects (Katz & Mazer, 2009; O'Rourke & Wosnitzer, 2016).
Association Between Opioid Use and Risk of Erectile Dysfunction: A Systematic Review and Meta-Analysis
2017, Journal of Sexual MedicineSexual Consequences of Post-SSRI Syndrome
2017, Sexual Medicine ReviewsA phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a High-Affinity Mu-Opioid Receptor Antagonist) in Premenopausal women diagnosed with Female Sexual Arousal Disorder (FSAD)
2013, Journal of Sexual MedicineCitation Excerpt :It is a component of FSD, which is a prevalent condition that is under‐recognized and undertreated [36]. FSAD is currently managed primarily through psychosexual therapy or hormonal therapy, and although previous attempts for medical treatment often focused on peripherally acting drugs like sildenafil [18] and aprostadil [37], a central component to its pathophysiology and a possible role for mu‐opioid receptors has been suggested [20-29]. The aim of this phase 2 proof of concept study was to evaluate the effects of CP‐866,087, a centrally acting, selective mu‐opioid receptor antagonist, in premenopausal women with FSAD.